MARKER THERAPEUTICS INC (MRKR)

Company Profile

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 67 full-time employees. The company went IPO on 2016-11-08. The firm specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The company has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. The company has three multiTAA-specific T cell therapies through clinical development, including Autologous multiTAA-specific T cell therapies, Allogeneic multiTAA-specific T cell therapies and Off-the-shelf multiTAA-specific T cell therapies. The company is also focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer. Autologous multiTAA-specific T cell therapies target the NY-ESO-1, PRAME, MAGE-A4, Survivin and SSX2 antigens.

Company Info

MARKER THERAPEUTICS INC

4551 Kennedy Commerce Dr.

Houston TEXAS 77027

P: 17134006400

CEO: Peter Hoang

Employees: 67

Website: https://markertherapeutics.com/